Images List Premium Download Classic

Diabetes

Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Proteins increasing pancreatic beta cell number and methods of use
University Of Oregon
October 12, 2017 - N°20170292115

Disclosed herein are bacterial proteins that increase pancreatic beta (β) cell number and/or proliferation, methods of increasing β cell number and/or proliferation using such proteins, and methods of treating or inhibiting diabetes in a subject by administering such proteins to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid ...
Growth differentiation factor 15 (gdf-15) polypeptides
Amgen Inc.
October 12, 2017 - N°20170291929

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Oral spray containing ixeris dentata nakai extract as active ingredient for preventing or treating xerostomia ...
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290872

When the ixeris dentata nakai extract is administered using the formulation of the present invention, the ixeris dentata nakai extract is sublingually sprayed through the spray formulation, and thus can be directly locally administered to a salivary gland tissue having an activity to induce secretion of saliva. Therefore, saliva secretion can be induced by rapid absorption of the active ingredient ...
Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290851

The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula i. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula i and a ...
Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Endorecherche, Inc.
October 12, 2017 - N°20170290847

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Peptides having reduced toxicity that stimulate cholesterol efflux
The Regents Of The University Of California
October 05, 2017 - N°20170283480

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e. G., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also ...
Compounds and methods for kinase modulation, and indications therefor
The Regents Of The University Of California
October 05, 2017 - N°20170283423

In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, ...
Indole derivatives for the prevention and/or treatment of diabetes and associated metabolic disorders
Centro De Investigacion Biomedica En Red (ciber)
October 05, 2017 - N°20170283378

The invention relates to substituted heterocyclic indole derivatives of formula (i), which act as activators of the amp-activated protein kinase (ampk) and to the use of them for the treatment and prevention of diseases or disorders regulated by ampk. As a result, these compounds can be used for the treatment of inflammatory, autoimmune, cardiovascular, neurological diseases and cancer.
Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
Biocrine Ab
October 05, 2017 - N°20170281763

Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (als) by inhibiting igg-mediated activation of voltage-gated calcium channels (vgccs) in cells of the subject, by one or more of removing igg from blood of the subject, blocking igg from activating vgccs in the subject; or blocking vgccs in the subject are described, as ...
Multi-cbv vaccine for preventing or treating type i diabetes
Vactech Oy
October 05, 2017 - N°20170281748

The invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective ...
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
Zealand Pharma A/s
October 05, 2017 - N°20170281709

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
Pharmaceutical compositions and methods for the treatment of diabetes
University Of Limerick
October 05, 2017 - N°20170281607

This invention relates to compositions and methods for treating type i diabetes. Compositions of the invention include active compounds such as harmine, indy, or derivatives thereof to induce reproduction of beta cells. These active compounds are provided in amounts that have poor clinical efficacy on their own, but when administered at a sub-threshold dose in combination with compounds such as ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Elisa for vegf
Genentech, Inc.
September 28, 2017 - N°20170276683

The vascular endothelial growth factor (vegf) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich elisa methods and kits for vegf as an antigen are provided to detect types of vegf levels in biological samples from animal models and human patients and can ...
Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting ...
Eastern Virginia Medical School
September 28, 2017 - N°20170275591

Methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes. Nox-1 inhibitors are also disclosed.
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (...
Amgen Inc.
September 28, 2017 - N°20170275370

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a glp-1 receptor agonist.
Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170275274

The present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
The Regents Of The University Of California
September 28, 2017 - N°20170275249

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i. E., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ...
Novel antagonists of the glucagon receptor
Metabasis Therapeutics, Inc.
September 28, 2017 - N°20170275246

The present invention provides for novel compounds of formula (i) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a ...
Polymeric stabilizing formulations
Nano Precision Medical, Inc.
September 28, 2017 - N°20170274089

The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention.
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273966

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Loading